# EDGAR Filing Document

**Accession Number:** 0001711754
**File Stem:** 0001213900-26-021120
**Filing Date:** 2026-2
**Character Count:** 8188
**Document Hash:** b7d8c1c11e68cd2aa9e9a144fe39b5c7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-021120.hdr.sgml**: 20260227

**ACCESSION NUMBER**: 0001213900-26-021120

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 70

**CONFORMED PERIOD OF REPORT**: 20260227

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260227

**DATE AS OF CHANGE**: 20260227

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Inmune Bio, Inc.
- **CENTRAL INDEX KEY:** 0001711754
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 475205835
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38793
- **FILM NUMBER:** 26693106

**BUSINESS ADDRESS:**
- **STREET 1:** 225 NE MIZNER BLVD, SUITE 640
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33432
- **BUSINESS PHONE:** 8589643720

**MAIL ADDRESS:**
- **STREET 1:** 225 NE MIZNER BLVD, SUITE 640
- **CITY:** BOCA RATON
- **STATE:** FL
- **ZIP:** 33432

?xml version='1.0' encoding='ASCII'?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): February 27, 2026

---

| |
|:---|
| **INMUNE BIO INC.** |
| (Exact name of registrant as specified in charter) |

---

---

| | | |
|:---|:---|:---|
| **Nevada** | **001-38793** | **47-5205835** |
| (State or other jurisdiction | (Commission File Number) | (IRS Employer |
| of incorporation) |  | Identification No.) |

---

**<u>225 NE Mizner Blvd., Suite 640, Boca Raton, Florida 33432</u>**

(Address of Principal Executive Offices) (Zip Code)

**<u>(561) 710-0512</u>**

(Registrant's Telephone Number, Including Area Code)

**<u>Not Applicable</u>**

(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (<u>see</u> General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | |
|:---|:---|
| **Title of each class** | **Name of each exchange on which registered** |
| Common Stock, par value $0.001 per shares INMB | The NASDAQ Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

**Item 7.01. Regulation FD Disclosure.**

INmune Bio Inc. (the "Company") has prepared a slide deck that the Company intends to use in presentations from time to time (the "Presentation"). The Presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K is furnished and shall not be deemed to be "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in any such filing.

**Item 9.01 Financial Statements and Exhibits.**

(d) Exhibits

---

| | |
|:---|:---|
| **Exhibit No**. | **Description** |
| 99.1 | [Investor Presentation](ea0226202601_ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **INMUNE BIO INC.** | **INMUNE BIO INC.** |
| Date: February 27, 2026 | By: | */s/ David Moss* |
|  | Name: | David Moss |
|  | Title: | Chief Executive Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](ea0226202601_ex99-1img1.jpg)

![](ea0226202601_ex99-1img2.jpg)

![](ea0226202601_ex99-1img3.jpg)

![](ea0226202601_ex99-1img4.jpg)

![](ea0226202601_ex99-1img5.jpg)

![](ea0226202601_ex99-1img6.jpg)

![](ea0226202601_ex99-1img7.jpg)

![](ea0226202601_ex99-1img8.jpg)

![](ea0226202601_ex99-1img9.jpg)

![](ea0226202601_ex99-1img10.jpg)

![](ea0226202601_ex99-1img11.jpg)

![](ea0226202601_ex99-1img12.jpg)

1. Pain relief 2. Itch relief 3. Mental health children/YP 4. Impact of inflammation 5. GI issues e.g., dysphagia Prioritisation survey 865 members EB global community 2024 - Top 5 issues What Treatments do People Living with DEB Want Right Now? 12

![](ea0226202601_ex99-1img13.jpg)

![](ea0226202601_ex99-1img14.jpg)

![](ea0226202601_ex99-1img15.jpg)

![](ea0226202601_ex99-1img16.jpg)

![](ea0226202601_ex99-1img17.jpg)

![](ea0226202601_ex99-1img18.jpg)

![](ea0226202601_ex99-1img19.jpg)

![](ea0226202601_ex99-1img20.jpg)

![](ea0226202601_ex99-1img21.jpg)

![](ea0226202601_ex99-1img22.jpg)

![](ea0226202601_ex99-1img23.jpg)

![](ea0226202601_ex99-1img24.jpg)

![](ea0226202601_ex99-1img25.jpg)

![](ea0226202601_ex99-1img26.jpg)

• Beyond topical care : First - in - class systemic therapy addressing multi - organ pathology of RDEB • CORDStrom i.v. infusions significantly improve multiple SYSTEMIC symptoms of RDEB and improve clinical skin scores in a randomised, double blind, placebo - controlled trial • EBDASI C iscorEB skin scores • Itch • Multiple pain indices • Quality of life • Excellent safety profile : • all age groups • All patient disease severity groups • Commercial readiness : • scale - out and scale - up options • Clinician - friendly packaging and supply chain delivery • CMC locked • Potency assays validated • Regulatory engagement underway and on time INmune Bio is moving from a clinical development company to a commercial provider 26 CORDStrom RDEB Summary

![](ea0226202601_ex99-1img27.jpg)

![](ea0226202601_ex99-1img28.jpg)

![](ea0226202601_ex99-1img29.jpg)

![](ea0226202601_ex99-1img30.jpg)

![](ea0226202601_ex99-1img31.jpg)

![](ea0226202601_ex99-1img32.jpg)

![](ea0226202601_ex99-1img33.jpg)

![](ea0226202601_ex99-1img34.jpg)

![](ea0226202601_ex99-1img35.jpg)

![](ea0226202601_ex99-1img36.jpg)

![](ea0226202601_ex99-1img37.jpg)

![](ea0226202601_ex99-1img38.jpg)

![](ea0226202601_ex99-1img39.jpg)

![](ea0226202601_ex99-1img40.jpg)

![](ea0226202601_ex99-1img41.jpg)

![](ea0226202601_ex99-1img42.jpg)

• Cutis aplasia - months to heal • Wounds heal • Weight gain satisfactory • Relatively stable period Phase 1: 0 to 18 months

![](ea0226202601_ex99-1img43.jpg)

![](ea0226202601_ex99-1img44.jpg)

![](ea0226202601_ex99-1img45.jpg)

![](ea0226202601_ex99-1img46.jpg)

![](ea0226202601_ex99-1img47.jpg)

![](ea0226202601_ex99-1img48.jpg)

![](ea0226202601_ex99-1img49.jpg)

![](ea0226202601_ex99-1img50.jpg)

![](ea0226202601_ex99-1img51.jpg)

![](ea0226202601_ex99-1img52.jpg)

![](ea0226202601_ex99-1img53.jpg)

![](ea0226202601_ex99-1img54.jpg)

![](ea0226202601_ex99-1img55.jpg)

![](ea0226202601_ex99-1img56.jpg)

![](ea0226202601_ex99-1img57.jpg)